Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Damora Therapeutics, Inc.

$21.23

-0.19 (-0.89%)

Market Cap
1.56 B
EPS
-
P/E Ratio
-
Value Trade
7.18 M
8.07 %
Week
-6.61 %
1 Month
-15.5 %
3 Month
49.09 %
6 Month
-79.88 %
5 Year
-93.25 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
1.75 M
52 Week Range
2.45 - 38.33
% held by Insiders
25.3 %
% held by Institutions
74.12 %
Enterprise Value
1.56 B
Total Shares
61.55 M
Short %
3.05 %
Float Shares
45.63 M
Company Description
HQ: 221 CRESCENT STREET, WALTHAM, ...
Employees:7
https://www.damoratx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
IND Submission example
DMR-001 mutant-calreticulin essential thrombocythemia and myelofibrosis
IND
—
Biologics
Hematologic System
DMR-001 mutant-calreticulin essential thrombocythemia and myelofibrosis
IND
—
Biologics
Hematologic System
DMR-001 mutant-calreticulin essential thrombocythemia and myelofibrosis
IND
—
Biologics
Hematologic System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in DMRA
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
DMRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DMRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DMRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
DMRA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
DMRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DMRA
May 13, 2026
DMRAGeneral

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Damora Therapeutics reported strong first-quarter results for 2026, highlighting significant progress in its mutCALR-targeted therapy pipeline. The company is on track to submit regulatory filings for its lead programs, DMR-001 and DMR-002, in mid-2026. Despite a net loss of $27.8 million, Damora maintains a robust cash position, expected to fund operations into 2029.

Read more →
DMRA
May 1, 2026
DMRAGeneral

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics has announced the granting of equity awards to two new non-executive employees as part of their inducement strategy under Nasdaq Listing Rule 5635(c)(4). The grants include non-qualified stock options for a total of 57,500 shares, with a defined vesting schedule. This move aims to enhance the company's capabilities in developing treatments for blood disorders.

Read more →
Competitive Position
How DMRA ranks across every disease it competes in
Competitive Position is a premium feature
See how DMRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial